Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SL228P, officially "RNA, 7SL, cytoplasmic 228, pseudogene," is a non-coding genomic locus classified as a **pseudogene** and part of the large family of 7SL RNA-derived sequences in the human genome[1][5][3]. Canonical 7SL RNA is the functional RNA component of the signal recognition particle (SRP), a ribonucleoprotein complex essential for targeting nascent proteins to the endoplasmic reticulum membrane[6][7]. In contrast, pseudogenes like RN7SL228P **do not produce active proteins or functional RNAs, but result from reverse transcription events and insertion into the genome**[3][5]. While some pseudogenes can act as regulatory non-coding RNAs influencing their parent gene (by mechanisms such as antisense RNA, microRNA sponging, or competitive binding to RNA-binding proteins), there is currently no evidence linking RN7SL228P to such a role[1][4]. Its annotation is for genomic reference, not for functional or clinical relevance. **Key notes:** - The presence of "pseudogene" in the name indicates that this locus is *not* a functional gene or therapeutic receptor/enzyme but a genomic relic[1][5][3]. - The gene product does **not participate in canonical biological processes or disease mechanisms**, nor is it recognized as a druggable target. - Current literature does not support any use or relevance as a biomarker, nor any safety concern related to RN7SL228P. **Structured information:** - Use the full canonical name "RNA, 7SL, cytoplasmic 228, pseudogene" for this locus. - It should not be listed as a therapeutic target or considered actively in drug discovery endeavors.
None; Not a canonical druggable molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 228, pseudogene (RN7SL228P).